MedPath

Commons, Marty

🇺🇸United States
Ownership
-
Employees
-
Market Cap
-
Website

A Study to Investigate LDL-cholesterol Lowering With Inclisiran Compared to Bempedoic Acid in Patients With Atherosclerotic Cardiovascular Disease.

Phase 4
Recruiting
Conditions
Hypercholesterolemia
Interventions
First Posted Date
2024-05-29
Last Posted Date
2024-12-27
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
400
Registration Number
NCT06431763
Locations
🇩🇪

Novartis Investigative Site, Voelklingen, Germany

Clinical Study of Asciminib in Previously Treated Indian Patients With Ph+ CML-CP Without T315I Mutation and in Patients With Ph+ CML-CP With T315I Mutation

Phase 4
Not yet recruiting
Conditions
Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase
Interventions
First Posted Date
2024-05-24
Last Posted Date
2024-05-28
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
85
Registration Number
NCT06427811

Pharmacokinetics Study of Ianalumab in Chinese Participants With Autoimmune Diseases

Phase 1
Not yet recruiting
Conditions
Sjogren Disease
Systemic Lupus Erythematosus
Interventions
First Posted Date
2024-05-13
Last Posted Date
2024-05-13
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
12
Registration Number
NCT06411639

Home Reported Outcomes in PNH

Recruiting
Conditions
Paroxysmal Nocturnal Hemoglobinuria
Interventions
Other: PNH-relevant therapies
First Posted Date
2024-05-13
Last Posted Date
2024-07-03
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
128
Registration Number
NCT06411626
Locations
🇺🇸

Novartis Investigative Site, East Hanover, New Jersey, United States

Care Pathway and Associated Costs of Patients Treated With CAR T-cells Based on SNDS Data

Completed
Conditions
Diffuse Large B-cell Lymphoma
Acute Lymphoblastic Leukemia (ALL)
First Posted Date
2024-04-30
Last Posted Date
2024-04-30
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
602
Registration Number
NCT06392763
Locations
🇫🇷

Novartis, Rueil-Malmaison, France

Iptacopan in Patients With ANCA Associated Vasculitis

Phase 2
Recruiting
Conditions
Anti-Neutrophil Cytoplasm Antibodies (ANCA) Associated Vasculitis
Interventions
First Posted Date
2024-04-29
Last Posted Date
2024-10-08
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
78
Registration Number
NCT06388941
Locations
🇹🇷

Novartis Investigative Site, Pendik Istanbul, Turkey

A Clinical Study to Evaluate the Safety and Effectiveness of Inclisiran Sodium in Indian Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia

Phase 4
Recruiting
Conditions
Primary Hypercholesterolemia
Mixed Dyslipidemia
Interventions
First Posted Date
2024-04-26
Last Posted Date
2024-12-27
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
65
Registration Number
NCT06386419
Locations
🇮🇳

Novartis Investigative Site, Kolkata, West Bengal, India

Modifying PEST for Psoriatic Arthritis Screening

Not Applicable
Not yet recruiting
Conditions
Plaque Psoriasis
Psoriatic Arthritis
Interventions
Diagnostic Test: PEST Screening group
First Posted Date
2024-04-24
Last Posted Date
2024-04-24
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
502
Registration Number
NCT06382051

NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer.

Phase 1
Recruiting
Conditions
Metastatic Neuroendocrine Prostate Cancer
Interventions
Drug: [68Ga]Ga-PSMA-11
Drug: [68Ga]GA-DOTA-TATE
Drug: [68Ga]Ga-NeoB
Drug: [177Lu]Lu-PSMA-617
Drug: [177Lu]Lu-DOTA-TATE
Drug: [177Lu]Lu-NeoB
Drug: Gonadotropin-releasing hormone (GnRH) analogues
Drug: L-Lysine HCl-L-Arginine HCl, 2.5 %,
Drug: GnRH antagonists
Drug: Antiemetics & antinauseants
Drug: Metoclopramide
First Posted Date
2024-04-23
Last Posted Date
2024-12-24
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
36
Registration Number
NCT06379217
Locations
🇬🇧

Novartis Investigative Site, Sutton, Surrey, United Kingdom

🇺🇸

Nebraska Cancer Specialists, Omaha, Nebraska, United States

🇺🇸

Memorial Sloan Kettering Cancer Ctr, New York, New York, United States

A Phase I Study of [177Lu]Lu-EVS459 in Patients With Ovarian and Lung Cancers

Phase 1
Not yet recruiting
Conditions
Lung Cancer
Ovarian Cancer
Interventions
Drug: [68Ga]Ga-EVS459
Drug: [177Lu]Lu-EVS459
First Posted Date
2024-04-19
Last Posted Date
2024-04-19
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
96
Registration Number
NCT06376253
Locations
🇮🇱

Novartis Investigative Site, Tel Aviv, Israel

© Copyright 2025. All Rights Reserved by MedPath